Abbott’s line of next-generation heart rhythm devices gains FDA approval
The FDA has approved Abbott’s line of Gallant implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator solutions.
The devices offer numerous new features, including an improved battery, MRI compatibility and Bluetooth connectivity. They can also be paired with Abbott’s smartphone application for connecting doctors with their patients.
“We are focused on developing and delivering life-changing technologies that impact patient care in a meaningful way,” Randel Woodgrift, Abbott’s senior vice president of cardiac rhythm management, said in a statement. “The Gallant devices are the latest example of how Abbott is driving innovation to meet changing healthcare needs and helping to improve connectivity and engagement between patients and their doctors.”
“The FDA's approval of Abbott's Gallant devices enables doctors to provide a more collaborative approach to treatment plans and the increased bond between a patient and provider will lead to better outcomes for all,” added Raffaele Corbisiero, MD, of the Deborah Heart and Lung Center in Brown Mills, New Jersey.
Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.